Protein lipidation in plants: requirements and potential for the production of lipoprotein vaccines
Final Report Abstract
Although some final experiments, especially the immunogenicity studies, are still in progress the project could be successfully completed. One downside is that we were not able to ultimately determine the exact nature of the lipid moiety in plant‐produced lipoproteins. It turned out to be extremely problematic, time and resource consuming and further analysis could not be justified in the limited capacity of this project. The second problem we faced during the project was the instability of a number of recombinant proteins in the chloroplast which slowed down the progress of the project extremely. However, we sorted out factors influencing the stability of bacterial proteins and developed transient expression modes to obtain sufficient amounts of recombinant proteins for further studies. The most surprising result was that for all tested proteins (OspA, Omp16, and Omp19) the lipid moiety was not necessary for immunogenicity, contrary to most of the previous published reports. Hence, plants definitely could be a viable and economical source for recombinant bacterial antigens against Lyme disease as well as brucellosis.
Publications
- (2008) Biopharmaceuticals from plants: A multitude of options for posttranslational modifications. In: Biotech. Gen. Eng. Rev.25. Keith Harding, Ed.
Warzecha, H.
- (2010) Novel Medicinal Plants for the Production and Delivery of Vaccines. In: Medicinal Plant Biotechnology. Arora, R., Ed. CABI, pp. 287‐ 302
Reichwein, S. Warzecha, H.
- (2010) Plastid Transformation. In: Genetic modification of plants ‐ agriculture, horticulture & forestry 64. Kempken, F. and Jung, C., Eds. Springer – pp 23‐38
Hennig, A., Warzecha, H.
- (2010). Solar‐powered factories for new vaccines and antibiotics. Trends Biotech. 28, 246‐252
Bock, R., Warzecha, H.
- The Protein Moiety of Brucella abortus Outer Membrane Protein 16 Is a New Bacterial Pathogen‐Associated Molecular Pattern That Activates Dendritic Cells In Vivo, Induces a Th1 Immune Response, and Is a Promising Self‐Adjuvanting Vaccine against Systemic and Oral Acquired Brucellosis. J Immunol 164: 5200‐5212 (2010)
Pasquevich KA, Garcia Samartino C, Coria LM, Estein SM, Zwerdling A, Ibanez AE, Barrionuevo P, Oliveira FS, Carvalho NB, Borkowski J, Oliveira SC, Warzecha H, Giambartolomei GH, Cassataro J
- An oral vaccine based on U‐Omp19 induces protection against B. abortus mucosal challenge by inducing an adaptive IL‐17 immune response in mice. PLoS One 6: e16203 (2011)
Pasquevich KA, Ibanez AE, Coria LM, Garcia Samartino C, Estein SM, Zwerdling A, Barrionuevo P, Oliveira FS, Seither C, Warzecha H, Oliveira SC, Giambartolomei GH, Cassataro J
- Hightech aus der grünen Apotheke. Biologie in unserer Zeit (BiuZ) 4/2011, S. 198‐205
Warzecha, H.
